183 related articles for article (PubMed ID: 38308119)
1. Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas.
Pedersen KK; Granborg JR; Lerche CM; Litman T; Olesen UH; Hædersdal M
Lasers Med Sci; 2024 Feb; 39(1):55. PubMed ID: 38308119
[TBL] [Abstract][Full Text] [Related]
2. Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo.
Olesen UH; Pedersen KK; Togsverd-Bo K; Biskup E; Nielsen AL; Jackerott M; Clergeaud G; Andresen TL; Haedersdal M
Lasers Surg Med; 2024 Mar; 56(3):239-248. PubMed ID: 38311811
[TBL] [Abstract][Full Text] [Related]
3. Topical delivery of vismodegib using ablative fractional laser and micro-emulsion formulation in vitro.
Olesen UH; Clergeaud G; Lerche CM; Andresen TL; Haedersdal M
Lasers Surg Med; 2019 Jan; 51(1):79-87. PubMed ID: 30152536
[TBL] [Abstract][Full Text] [Related]
4. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drugs and the regulation of Hedgehog genes GLI1 and PTCH1, a comparative study in nonmelanoma skin cancer cell lines.
Olesen UH; Bojesen S; Gehl J; Haedersdal M
Anticancer Drugs; 2017 Nov; 28(10):1106-1117. PubMed ID: 28799948
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
9. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
10. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
11. Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib.
Sternfeld A; Rosenwasser-Weiss S; Ben-Yehuda G; Shefer HK; Friedman-Gohas M; Yassur I; Tauber G; Bejar J; Olshinka A; Vardizer Y; Ad El D; Goldenberg-Cohen N
Sci Rep; 2020 Jan; 10(1):1244. PubMed ID: 31988301
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog signaling pathway: a novel target for cancer therapy: vismodegib, a promising therapeutic option in treatment of basal cell carcinomas.
Abidi A
Indian J Pharmacol; 2014; 46(1):3-12. PubMed ID: 24550577
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Tang JY; Ally MS; Chanana AM; Mackay-Wiggan JM; Aszterbaum M; Lindgren JA; Ulerio G; Rezaee MR; Gildengorin G; Marji J; Clark C; Bickers DR; Epstein EH
Lancet Oncol; 2016 Dec; 17(12):1720-1731. PubMed ID: 27838224
[TBL] [Abstract][Full Text] [Related]
14. Neo-adjuvant Vismodegib followed by radiation in locally advanced basal cell carcinoma.
Sabu DM; Kroes J; Gilham C; Fleming A; Kelleher FC
Curr Probl Cancer; 2021 Dec; 45(6):100736. PubMed ID: 33894989
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological Inhibition of Sonic Hedgehog Signaling Suppresses Tumor Development in a Murine Model of Intrahepatic Cholangiocarcinoma.
Cho K; Moon H; Seo SH; Ro SW; Kim BK
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948011
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of sonic hedgehog signaling-related molecules in basal cell carcinoma.
Kim HS; Kim YS; Lee C; Shin MS; Kim JW; Jang BG
PLoS One; 2019; 14(11):e0225511. PubMed ID: 31756206
[TBL] [Abstract][Full Text] [Related]
17. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
[TBL] [Abstract][Full Text] [Related]
18. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
20. Identification of anaplastic lymphoma kinase as a potential therapeutic target in Basal Cell Carcinoma.
Ning H; Mitsui H; Wang CQ; Suárez-Fariñas M; Gonzalez J; Shah KR; Chen J; Coats I; Felsen D; Carucci JA; Krueger JG
Oncotarget; 2013 Dec; 4(12):2237-48. PubMed ID: 24163262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
